文献速递乳腺癌支持与姑息治疗

HER2阳性早期乳腺癌化疗时长与患者报告结局:TRAIN-3研究结果

Chemotherapy duration and patient-reported outcomes in HER2-positive early breast cancer: Results from the TRAIN-3 study.
PubMed 文献 · Eur J Cancer · 2026-06-13

结果显示化疗周期较短者身体和角色功能保留更好、疲乏和神经病变更轻,24个月时总体健康状况临床有意义恶化比例在三组分别为26%、55%和46%。

要点

  • MRI引导缩短新辅助化疗可更好保留长期HRQOL
  • 化疗周期越长,疲乏和神经病变负担越重
  • 神经病变与12和24个月总体HRQOL较差相关

核心结论

  • MRI引导的较短新辅助化疗时长与HER2阳性早期乳腺癌患者HRQOL下降更轻和长期保留更好相关。
  • 这些发现支持将MRI引导的治疗降阶梯作为减轻生存者负担而不影响疗效的策略。

研究设计与样本

  • 按新辅助化疗周期数分为1-3周期组29例(32%)、4-6周期组26例(29%)和7-9周期组35例(39%)。
  • 使用EORTC QLQ-C30和QLQ-BR45问卷在基线及6、12、24个月评估HRQOL。

主要发现

  • 接受1-3周期化疗的患者相比更长化疗者持续报告身体和角色功能保留更好、疲乏更少、神经病变评分更低。
  • 24个月时总体健康状况临床有意义恶化的比例在1-3、4-6和7-9周期组分别为26%、55%和46%。
  • 更严重的神经病变与12个月和24个月时更差的总体HRQOL相关。

临床怎么用

  • 对于HER2阳性早期乳腺癌患者,可考虑基于乳腺MRI早期完全缓解引导缩短新辅助化疗时长。
  • 在治疗降阶梯决策中应关注患者报告结局,尤其是神经病变和疲乏的长期负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-HER2 based (neo)adjuvant chemotherapy has substantially improved outcomes for patients with stage II-III HER2-positive breast cancer but often leads to long-term toxicities that impair survivors' health-related quality of life (HRQOL). The TRAIN-3 study demonstrated that shortening neoadjuvant chemotherapy based on early complete response on breast MRI preserves efficacy. The impact of chemotherapy duration on HRQOL remains unclear. Here, we report the results from the pre-planned HRQOL analyses. METHODS: HRQOL was assessed at baseline, and at 6, 12 and 24 months using the EORTC QLQ-C30 and QLQ-BR45 questionnaires. Patients with baseline and at least one follow-up assessment were included for this analysis. RESULTS: Ninety patients were evaluable: 29 (32%) received 1-3 cycles, 26 (29%) received 4-6 cycles, and 35 (39%) received 7-9 cycles of neoadjuvant chemotherapy. Patients receiving 1-3 cycles reported consistently better preservation of physical and role functioning, less fatigue, and lower neuropathy scores compared to those receiving longer chemotherapy. At 24 months, clinically meaningful deterioration in global health status was observed in 26%, 55% and 46% of patients in the 1-3, 4-6 and 7-9 cycle groups, respectively. Greater neuropathy was associated with worse global HRQOL at both 12 and 24 months. CONCLUSION: MRI-guided shorter neoadjuvant chemotherapy duration is associated with less pronounced declines and better long-term preservation of HRQOL in patients with early HER2-positive breast cancer. These findings support MRI-guided treatment de-escalation as a strategy to reduce survivorship burden without compromising efficacy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Louis FM, der Voort AV, Egeler MD, et al. Chemotherapy duration and patient-reported outcomes in HER2-positive early breast cancer: Results from the TRAIN-3 study. Eur J Cancer. 2026. PMID: 42308862. doi:10.1016/j.ejca.2026.116882

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。